EP64: Racetams and their clinical PERFORMANCE ability
Alright! In this podcast, we break down some of the clinical application of the major racetams.
Typically, we think of Racetams as performance enhancing, and don’t usually discuss them out of the context of making our brains work better NOW. And one of the best guides on the internet on the performance use of Racetams can be found HERE, in the Racetam God Guide (FULLY DIGITAL – DOWNLOAD IT NOW).
But the clinical application for people that have cognitive malfunction is equally interesting.
We pull from a major study, examining the benefits of racetam nootropics for various cognitive dysfunction.
Here is a major snippet from the study, that outlines the basis for this podcast:
The major focus of the literature search was on articles demonstrating evidence-based clinical investigations during the past 10 years for the following therapeutic categories of CNS disorders: (i) cognition/memory; (ii) epilepsy and seizure; (iii) neurodegenerative diseases; (iv) stroke/ischaemia; and (v) stress and anxiety. In this article, piracetam-like compounds are divided into three subgroups based on their chemical structures, known efficacy and intended clinical uses. Subgroup 1 drugs include piracetam, oxiracetam, aniracetam, pramiracetam and phenylpiracetam, which have been used in humans and some of which are available as dietary supplements. Of these, oxiracetam and aniracetam are no longer in clinical use. Pramiracetam reportedly improved cognitive deficits associated with traumatic brain injuries. Although piracetam exhibited no long-term benefits for the treatment of mild cognitive impairments, recent studies demonstrated its neuroprotective effect when used during coronary bypass surgery. It was also effective in the treatment of cognitive disorders of cerebrovascular and traumatic origins; however, its overall effect on lowering depression and anxiety was higher than improving memory. As add-on therapy, it appears to benefit individuals with myoclonus epilepsy and tardive dyskinesia. Phenylpiracetam is more potent than piracetam and is used for a wider range of indications. In combination with a vasodilator drug, piracetam appeared to have an additive beneficial effect on various cognitive disabilities. Subgroup 2 drugs include levetiracetam, seletracetam and brivaracetam, which demonstrate antiepileptic activity, although their cognitive effects are unclear.
The study discusses: